2. Search Result
Search Result
Results for "

blood sugar

" in MedChemExpress (MCE) Product Catalog:

49

Inhibitors & Agonists

1

Screening Libraries

3

Biochemical Assay Reagents

4

Peptides

14

Natural
Products

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N0237
    Atractyloside A
    3 Publications Verification

    		 Others Cardiovascular Disease Others Cancer
    Atractyloside A possesses activities such as lowering blood pressure，reducing blood sugar，and anti-tumor effects.
    Atractyloside A
  • HY-107863
    Fructooligosaccharides

    Oligolevulose

    		 Biochemical Assay Reagents Metabolic Disease
    Fructooligosaccharides (Oligolevulose) is a beneficial sugar which can be produced by the microbial flora. Fructooligosaccharides had no significant effect on blood glucose, blood lipid and serum acetate in diabetic model .
    Fructooligosaccharides
  • HY-B2122
    Maltitol

    		PPAR Fatty Acid Synthase (FASN) Others
    Maltitol is an orally active polyol and sugar alcohol sweetener produced by the hydrogenation of maltose. Maltitol can replace sucrose and has characteristics of having a minor impact on blood sugar and potential prebiotic effects .
    Maltitol
  • HY-130003
    Hypoglycemic agent 1

    		Others Metabolic Disease
    Hypoglycemic agent 1 acts as a therapeutic and/or prophylactic agent for diabetes. Hypoglycemic agent 1 has an action for lowering blood sugar .
    Hypoglycemic agent 1
  • HY-N13221
    Apple Cider Vinegar Powder

    		Bacterial Reactive Oxygen Species Fungal Cardiovascular Disease Metabolic Disease Cancer
    Apple Cider Vinegar Powder is a soluble powdered form of apple cider vinegar. Apple Cider Vinegar Powder has anti-bacterial, anti-oxidant, and antibiotic properties and can help maintain the acid-base balance in the blood. Apple Cider Vinegar Powder can lower blood sugar and lipid levels. Apple Cider Vinegar Powder is used in research related to tumors, diabetes, and cardiovascular diseases .
    Apple Cider Vinegar Powder
  • HY-158037
    α-Glucosidase-IN-55

    		Glycosidase Metabolic Disease
    α-Glucosidase-IN-55 (Compound 8g) is an orally active and competitive alpha-glucosidase inhibitor, with IC50 and Ki values of 12.1 and 9.66 µM, respectively. α-Glucosidase-IN-55 can be used for the research into type 2 diabetes mellitus (T2DM) to improve blood sugar control and metabolic health .
    α-Glucosidase-IN-55
  • HY-N13205
    Mulberry Extract

    		Others Metabolic Disease
    Mulberry Extract is a mulberry extract, and its components include: Anthocyanidins. Mulberry Extract regulates sugar and lipid metabolism, lowers blood sugar and increases insulin secretion. Its blood sugar regulating effect may be attributed to the phytochemicals it contains, mainly 1-deoxynojirimycin, flavonoids, phenolic compounds and polysaccharides. .
    Mulberry Extract
  • HY-109089
    Epeleuton

    		Others Others
    Epeleuton is a second-generation synthetic n-3 fatty acid derivative that mainly targets the regulation of blood lipids, blood sugar and inflammatory responses. In clinical trials, Epeleuton significantly reduced triglycerides, very low-density lipoprotein cholesterol and total cholesterol without increasing low-density lipoprotein cholesterol levels. Epeleuton also significantly improved glycated hemoglobin (HbA1c) and fasting blood sugar levels. Epeleuton reduces markers of cardiovascular risk and endothelial dysfunction and has the potential to inhibit systemic inflammation and non-alcoholic fatty liver disease .
    Epeleuton
  • HY-149533
    α-Glucosidase-IN-34

    		Glycosidase Metabolic Disease
    α-Glucosidase-IN-34 (compound 7f) is a potent α-glucosidase inhibitor (IC50: 2.90 μM) and can be used in the study of type 2 diabetes and hyperglycemia .
    α-Glucosidase-IN-34
  • HY-149532
    α-Glucosidase-IN-33

    		Glycosidase Metabolic Disease
    α-Glucosidase-IN-33 (compound 7c) is a potent α-glucosidase inhibitor (IC50: 2.39 μM) and can be used in the study of type 2 diabetes and hyperglycemia .
    α-Glucosidase-IN-33
  • HY-12735
    SCH 900822

    		GCGR Metabolic Disease Endocrinology
    SCH 900822 is a potent and selective glucagon receptor (hGCGR) antagonist that blocks the binding of glucagon to its receptor, thereby reducing hepatic glycogenolysis and gluconeogenesis, thereby lowering blood glucose production. SCH 900822 can be used in the study of type 2 diabetes .
    SCH 900822
  • HY-B2122R
    Maltitol (Standard)

    		PPAR Fatty Acid Synthase (FASN) Others
    Maltitol (Standard) is the analytical standard of Maltitol (HY-B2122). This product is intended for research and analytical applications. Maltitol is an orally active polyol and sugar alcohol sweetener produced by the hydrogenation of maltose. Maltitol can replace sucrose and has characteristics of having a minor impact on blood sugar and potential prebiotic effects .
    Maltitol (Standard)
  • HY-164781
    KOTX1

    		Aldehyde Dehydrogenase (ALDH) Metabolic Disease
    KOTX1 is an orally active and selective ALDH1A3 inhibitor. KOTX1 improves glucose tolerance, insulin secretion and blood sugar levels in diabetic mouse models .
    KOTX1
  • HY-163652
    Glicetanile

    		Others Metabolic Disease
    Glicetanile is an orally active hypoglycemic agent, that stimulates the release of insulin from pancreatic beta cells, and lowers the blood sugar. Glicetanile exhibits potential in ameliorating the type 2 diabetes .
    Glicetanile
  • HY-124281
    9(R)-PAHSA

    		NF-κB Akt Autophagy PI3K Others
    9(R)-PAHSA is a R-enantiomer of 9-PAHSA. 9-PAHSA is an orally available anti-inflammatory lipid that lowers blood sugar and reduces inflammation .
    9(R)-PAHSA
  • HY-124281A
    9(S)-PAHSA

    		Drug Isomer NF-κB Others
    9(S)-PAHSA is a S-enantiomer of 9-PAHSA. 9-PAHSA is an orally available anti-inflammatory lipid that lowers blood sugar and reduces inflammation .
    9(S)-PAHSA
  • HY-168140
    TGR5 agonist 6

    		G protein-coupled Bile Acid Receptor 1 Cancer
    TGR5 agonist 6 (compund 22b) is a non-systemic gut-targeted TGR5 agonist with significant and sustained blood sugar-lowering effects and an acceptable safety profile .
    TGR5 agonist 6
  • HY-N11728
    2,7"-Phloroglucinol-6,6'-bieckol

    		Amylases Glycosidase Metabolic Disease
    2,7"-Phloroglucinol-6,6'-bieckol is an orally active dual α-amylase/α-glucosidase inhibitor with IC50 values of 6.94 μM and 23.35 μM respectively. 2,7"-Phloroglucinol-6, 6'-bieckol alleviates postprandial hyperglycemia in diabetic mice. 2,7"-Phloroglucinol-6,6'-bieckol can be used in diabetes research .
    2,7
  • HY-109018A
    Velagliflozin proline
    1 Publications Verification

    		 SGLT Metabolic Disease
    Velagliflozin proline is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor with antidiabetic activity. Velagliflozin proline reduces renal glucose reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations .
    Velagliflozin proline
  • HY-N0640
    Kuromanin chloride
    5+ Cited Publications

    Chrysontemin; Cyanidin 3-O-glucoside chloride

    		 CD38 Neurological Disease Metabolic Disease
    Kuromanin chloride (Chrysontemin) is derived from mulberry leaves and has the effect of increasing blood sugar concentration and maintaining lipid metabolism balance to reduce obesity. Kuromanin chloride can inhibit CD38 enzymatic activities .
    Kuromanin chloride
  • HY-142162
    LSN3318839

    		GCGR Metabolic Disease
    LSN3318839 is an orally active positive modulator of the glucagon-like peptide-1 receptor (GLP-1R). LSN3318839 can increase the secretion of insulin and has the effect of lowering blood sugar .
    LSN3318839
  • HY-117172
    CP320626

    		Phosphorylase Metabolic Disease
    CP320626 is a potent inhibitor of human liver glycogen phosphorylase (IC50=205 nM). CP320626 reduces blood glucose in diabetic mice without changing plasma insulin levels. CP320626 can be used in the study of type 2 diabetes .
    CP320626
  • HY-117985A
    Evogliptin hydrochloride

    DA-1229 hydrochloride

    		 Dipeptidyl Peptidase Metabolic Disease Endocrinology
    Evogliptin hydrochloride (DA-1229 hydrochloride) is an orally available DPP4 inhibitor with significant and durable hypoglycemic effects in mouse models. Evogliptin hydrochloride also inhibits the generation of inflammatory and fibrotic signals in hepatocytes by inducing autophagy. Evogliptin hydrochloride can be used in the research of type 2 diabetes, osteoporosis, renal impairment and chronic liver inflammation .
    Evogliptin hydrochloride
  • HY-108719
    Insulin glargine

    		Insulin Receptor Akt Metabolic Disease Cancer
    Insulin glargine is a long-acting insulin analog. Insulin glargine has the effect of lowering blood sugar and can be used in the research of diabetes. In addition, high doses of Insulin glargine can promote the proliferation of bladder cancer cells .
    Insulin glargine
  • HY-109018B
    Velagliflozin proline hydrate
    1 Publications Verification

    		 SGLT Metabolic Disease
    Velagliflozin proline hydrate is the clinical form of Velagliflozin (HY-109018). Velagliflozin is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor with antidiabetic activity. Velagliflozin reduces renal glucose reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations .
    Velagliflozin proline hydrate
  • HY-159496
    Dyrk1A-IN-10

    		DYRK Metabolic Disease
    Dyrk1A-IN-10 (compound B4) is a DYRK1A inhibitor with antidiabetic activity. Dyrk1A-IN-10 can promote pancreatic β-cell proliferation, increase insulin secretion, and lower blood sugar .
    Dyrk1A-IN-10
  • HY-169566
    EGFR-IN-146

    		EGFR AMPK Metabolic Disease
    EGFR-IN-146 is an EGFR inhibitor that can inhibit the EGFR signaling pathway and improve insulin sensitivity by activating the AMPK pathway, which can effectively reduce blood sugar levels and body weight. EGFR-IN-146 has great potential in the study of diabetes and obesity .
    EGFR-IN-146
  • HY-136631
    PF-04279405

    		Glucokinase Metabolic Disease
    PF-04279405 is a potent and full-acting glucokinase (GK) agonist (EC50=23 nM). Glucokinase (GK) is an enzyme responsible for the conversion of glucose to glucose-6-phosphate and plays a key role in maintaining blood glucose homeostasis. PF-04279405 can be used in the research of type 2 diabetes .
    PF-04279405
  • HY-N0640R
    Kuromanin (chloride) (Standard)

    		CD38 Neurological Disease Metabolic Disease
    Kuromanin (chloride) (Standard) is the analytical standard of Kuromanin (chloride). This product is intended for research and analytical applications. Kuromanin chloride (Chrysontemin) is derived from mulberry leaves and has the effect of increasing blood sugar concentration and maintaining lipid metabolism balance to reduce obesity. Kuromanin chloride can inhibit CD38 enzymatic activities .
    Kuromanin (chloride) (Standard)
  • HY-170569
    Cetagliptin

    		Dipeptidyl Peptidase Cytochrome P450 P-glycoprotein Metabolic Disease
    Cetagliptin is an orally active inhibitor for dipeptidyl peptidase 4 (DPP-4) and CYP2D6 (IC50 of 6 µM). Cetagliptin is a substrate for P-glycoprotein. Cetagliptin reduces the GLP-1 degradation, maintains the level of postprandial blood sugar, and can be used in type 2 diabetes mellitus research .
    Cetagliptin
  • HY-142162A
    (S,R)-LSN3318839

    		GCGR Metabolic Disease
    (S,R)-LSN3318839 is the stereoisomer of LSN3318839 (HY-142162). LSN3318839 is an orally active positive modulator of the glucagon-like peptide-1 receptor (GLP-1R). LSN3318839 can increase the secretion of insulin and has the effect of lowering blood sugar .
    (S,R)-LSN3318839
  • HY-128530
    Tetrathiomolybdate

    		Cuproptosis Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
    Tetrathiomolybdate, an orally active anti-copper agent, reduces copper levels in the body. Tetrathiomolybdate has a protective effect on collagen-induced arthritis in mice. Tetrathiomolybdate also reduces blood sugar, but has no effect on mice with hereditary diabetes (db/db). Tetrathiomolybdate inhibit angiogenesis, also shows antiangiogenic effects in malignant pleural mesothelioma .
    Tetrathiomolybdate
  • HY-109556
    Insulin Detemir

    		Akt ERK Metabolic Disease
    Insulin Detemir is an artificial insulin, shows effect on controlling blood sugar levels. Insulin Detemir stimulates GLP-1 secretion as a consequence of enhanced Gcg expression by a mechanism involving activation of Akt- and/or extracellular signal-regulated kinase (ERK)-dependent-cat and CREB signaling pathways. Insulin Detemir can be used for type 2 diabetes research .
    Insulin Detemir
  • HY-N0378
    D-Mannitol
    5+ Cited Publications

    Mannitol; Mannite

    		 Endogenous Metabolite Apoptosis Adrenergic Receptor PGC-1α PKA Cardiovascular Disease Metabolic Disease Cancer
    D-Mannitol (Mannitol) is an oral, resistant sugar widely used in the food and pharmaceutical industries to promote the absorption and retention of calcium and magnesium through cecal fermentation, while acting as a osmotic diuretic to reduce tissue edema. D-Mannitol can enhance brown fat formation, improve insulin effect, reduce blood sugar levels, And through the start the β3-adrenergic receptor (β3-AR), PGC1α and PKA induced by means of white fat cells into brown fat cells .
    D-Mannitol
  • HY-120657
    9-PAHSA

    		Endogenous Metabolite Cardiovascular Disease Inflammation/Immunology
    9-PAHSA is an orally available anti-inflammatory lipid that lowers blood sugar and reduces inflammation. 9-PAHSA also improved carotid vascular calcification and attenuates cardiac hypertrophy and dysfunction in db/db mice. 9-PAHSA increases the viability of steatosis primary mouse hepatocytes (PMH). 9-PAHSA can be used in research on diabetes, inflammation, and cardiovascular disease .
    9-PAHSA
  • HY-W050031R
    (S)-3-Hydroxybutanoic acid (Standard)

    (S)-β-Hydroxybutanoic acid (Standard); L-(+)-3-Hydroxybutyric acid (Standard); L-β-Hydroxybutyric acid (Standard)

    		 Endogenous Metabolite Others
    (S)-3-Hydroxybutanoic acid (Standard) is the analytical standard of (S)-3-Hydroxybutanoic acid (HY-W050031). This product is intended for research and analytical applications. (S)-3-Hydroxybutanoic acid is a metabolite and a disease marker for depression. (S)-3-Hydroxybutanoic acid is synthesized in the liver from acetyl-CoA and can be used by the brain as an energy source when blood sugar is low.
    (S)-3-Hydroxybutanoic acid (Standard)
  • HY-128852
    N-Acetyl-D-galactosamine, 98%

    		Galectin Endogenous Metabolite Others
    N-Acetyl-D-galactosamine (GalNAc) is a terminal essential amino sugar derived from galactose and forms the antigens of blood group A in humans. N-Acetyl-D-galactosamine (GalNAc) interact with Soya bean agglutinin (SBA), hence decreasing the effects of SBA on cellular membrane permeability and tight junction protein expression in piglets . N-Acetyl-D-galactosamine (GalNAc) inhibits the hemagglutinating activity by the lectin .
    N-Acetyl-D-galactosamine, 98%
  • HY-N0378R
    D-Mannitol (Standard)
    5+ Cited Publications

    Mannitol(Standard); Mannite (Standard)

    		 Endogenous Metabolite Apoptosis Adrenergic Receptor PGC-1α PKA Cardiovascular Disease Metabolic Disease Cancer
    D-Mannitol (Standard) is the analytical standard of D-Mannitol. This product is intended for research and analytical applications. D-Mannitol (Mannitol) is an oral, resistant sugar widely used in the food and pharmaceutical industries to promote the absorption and retention of calcium and magnesium through cecal fermentation, while acting as a osmotic diuretic to reduce tissue edema. D-Mannitol can enhance brown fat formation, improve insulin effect, reduce blood sugar levels, And through the start the β3-adrenergic receptor (β3-AR), PGC1α and PKA induced by means of white fat cells into brown fat cells .
    D-Mannitol (Standard)
  • HY-113024R
    Pristanic acid (Standard)

    		Endogenous Metabolite Metabolic Disease
    D-Mannitol (Standard) is the analytical standard of D-Mannitol. This product is intended for research and analytical applications. D-Mannitol (Mannitol) is an oral, resistant sugar widely used in the food and pharmaceutical industries to promote the absorption and retention of calcium and magnesium through cecal fermentation, while acting as a osmotic diuretic to reduce tissue edema. D-Mannitol can enhance brown fat formation, improve insulin effect, reduce blood sugar levels, And through the start the β3-adrenergic receptor (β3-AR), PGC1α and PKA induced by means of white fat cells into brown fat cells .
    Pristanic acid (Standard)
  • HY-N7860
    Δ2-cis Eicosenoic acid

    		Others Infection
    Δ2-cis Eicosenoic acid is an α,β-unsaturated fatty acid that has been extracted from fresh water clams and purified. A related compound, 2-octadecenoic acid, has been shown to improve liver function and decrease blood sugar in streptozocin-induced diabetic rats. Δ2-cis Eicosenoic acid and its salts have potential medicinal use for treating diabetes and improving lipid metabolism.
    Δ2-cis Eicosenoic acid
  • HY-17444
    Tesaglitazar

    		PPAR Metabolic Disease Cancer
    Tesaglitazar is a dual-target PPARα/γ agonist with an EC50 of 13.4 μM for rat PPARα and 3.6 μM for human PPARα. Tesaglitazar affects lipid and glucose metabolism by activating PPARα and PPARγ receptors, and has the potential to improve blood sugar and relieve pain. Tesaglitazar can be used to induce in vivo tumor models and can be used in the study of type 2 diabetes, dyslipidemia, and neuropathic pain .
    Tesaglitazar
  • HY-159944
    PPARγ agonist 14

    		PPAR Neurological Disease Metabolic Disease Inflammation/Immunology
    PPARγ agonist 14 (compound 3) is a PPARy agonist (EC50=2.4 μM) with anti-diabetic activity. PPARγ agonist 14 can improve intracellular glucose uptake, promote insulin release, and lower blood sugar. In addition, PPARγ agonist 14 also improves mitochondrial function, reduces oxidative stress, and inhibits inflammatory factors. PPARγ agonist 14 can be used in the study of neurodegenerative diseases, neuroinflammatory diseases, and other diseases .
    PPARγ agonist 14
  • HY-B1245
    Salsalate
    2 Publications Verification

    Salicylsalicylic acid; Disalicylic acid

    		 Reactive Oxygen Species Inflammation/Immunology Cancer
    Salsalate is a potent antirheumatic drug with oral activity that reduces irritation during gastric absorption and avoids direct inhibition of cyclooxygenase. Salsalate not only has significant anti-inflammatory effects, but also reduces blood sugar levels, improves insulin resistance, and reduces the expression of cytokines. Salsalate can protect mice from metabolic disorders caused by high-fat diet and effectively improve the symptoms of type 2 diabetes, atherosclerosis and non-alcoholic steatohepatitis [2 ] .
    Salsalate
  • HY-W016715
    L-Cysteine hydrochloride hydrate
    5+ Cited Publications

    		 Endogenous Metabolite NF-κB Insulin Receptor Neurological Disease Metabolic Disease
    L-Cysteine hydrochloride hydrate is an orally active and essential amino acid, which acts as a precursor for biologically active molecules such as hydrogen sulphide (H2S), glutathione and taurine. L-Cysteine hydrochloride hydrate regulates CBS/H2S pathway, inhibits NF-κB activation and insulin and ghrelin secretion. L-Cysteine hydrochloride hydrate reduces blood sugar, vascular inflammation markers and appetite. L-Cysteine hydrochloride hydrate induces kidney damage. L-Cysteine hydrochloride hydrate can be used in the study of neurological diseases and diabetes .
    L-Cysteine hydrochloride hydrate
  • HY-P10302
    GLP-1R/GIPR agonist-1

    		GLP Receptor Insulin Receptor Metabolic Disease
    GLP-1R/GIPR AgonIST-1 is a double-receptor agonist for GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulin releasing peptide). GLP-1R/GIPR agonist-1 lowers blood sugar by mimicking the action of endogenous hormones GLP-1 and GIP, enhancing insulin secretion while inhibiting glucagon secretion. GLP-1R/GIPR agonist-1 can be used in the study of metabolic diseases such as diabetes, obesity, and non-alcoholic steatohepatitis (NASH) .
    GLP-1R/GIPR agonist-1
  • HY-Y0079
    D-Phenylalanine

    		Endogenous Metabolite Infection
    D-Phenylalanine is an atypical D-amino acid and an inhibitor of bacterial biofilm formation. D-Phenylalanine mainly replaces D-alanine (D-Ala) by incorporating into the fourth and fifth positions of bacterial peptidoglycan (PG), changing the cell wall structure, enhancing bacterial acid resistance and affecting biofilm formation. D-Phenylalanine may promote the secretion of peptide tyrosine tyrosine (PYY) in mammals by activating the intestinal GPR109B receptor. D-Phenylalanine can inhibit the maturation of microbial biofilms and promote the release of specific hormones. It can be used for antibacterial preservation, improving the yield of probiotics in the food industry, and studying appetite regulation and blood sugar control in metabolic diseases such as diabetes .
    D-Phenylalanine
  • HY-109692
    GPR120 Agonist 5

    		Free Fatty Acid Receptor Metabolic Disease Inflammation/Immunology
    GPR120 Agonist 5 (compound 12) is an agonist targeting GPR120 (EC50=1.2 μM). GPR120 Agonist 5 promotes the release of glucagon-like 1 (GLP-1) by binding to the GPR120 receptor, which in turn binds to its receptors on pancreatic beta cells, increasing insulin secretion and thereby lowering blood sugar levels. GPR120 Agonist 5 also helps reduce chronic low-grade inflammation, which plays an important role in the pathogenesis of obesity, insulin resistance, and type 2 diabetes. GPR120 Agonist 5 can be used to investigate the mechanism of action of GPR120 in metabolic and inflammatory diseases .
    GPR120 Agonist 5
  • HY-P10302A
    GLP-1R/GIPR agonist-1 (soduim)

    		GLP Receptor Metabolic Disease
    GLP-1R/GIPR agonist-1 soduim is the sodium salt form of GLP-1R/GIPR agonist-1 (HY-P10302). GLP-1R/GIPR agonist-1 soduim is a dual agonist for glucagon-like peptide-1 receptor (GLP-1R, EC50 is 0.57 nM) and glucose-dependent insulin releasing peptide receptor (GIPR, EC50 is 0.75 nM). GLP-1R/GIPR agonist-1 soduim lowers blood sugar by mimicking the action of endogenous hormones GLP-1 and GIP, enhancing insulin secretion while inhibiting glucagon secretion. GLP-1R/GIPR agonist-1 soduim can be used in the study of metabolic diseases such as diabetes, obesity, and non-alcoholic steatohepatitis (NASH) .
    GLP-1R/GIPR agonist-1 (soduim)
  • HY-W010934
    3β,5α,6β-Trihydroxycholestane

    		Biochemical Assay Reagents Others
    3β,5α,6β-Trihydroxycholestane is a steroid that occurs naturally in the body and is also found in certain foods. It belongs to a class of compounds known as cholestanes, which are closely related to the better known cholesterol. This particular compound is formed from cholesterol through a series of enzymatic reactions in the liver and other organs. It has been studied for its potential health benefits, including its ability to reduce inflammation and oxidative stress in the body. Some research suggests that it may also play a role in regulating blood sugar levels and improving insulin sensitivity. Despite these potential benefits, 3β,5α,6β-Trihydroxycholestane is not widely used as a supplement or medicine due to its relatively low content, focus on natural resources and limited research. However, researchers continue to investigate its potential uses and effects on human health.
    3β,5α,6β-Trihydroxycholestane

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: